Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Omeros Earnings Call: Key Takeaways

Omeros reported strong Yard-Temlia momentum with $35.9M net sales and positive operating cash flow, though European regulatory setbacks and a refusal to provide 2027 guidance remain key overhangs.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthYard-Temlia gross sales $41.8M (up 30%); net sales $35.9M (up 26%).
Mgmt ConfidenceHigh confidence in US launch momentum; disappointed by 'misguided' European CHMP decision.
Demand VisibilityUnique ordering accounts increased 49% to 109; P&T approvals at 80% top-centers.
Margin TrendsGross-to-net deductions increased to 14% from 11.5% due to 340B utilization.
Op. LeverageSecond consecutive quarter of positive operating cash flow at $13.3M.
Pricing PowerYard-Temlia holds pass-through status through June 2029, exempting it from 340B cuts.
Vol vs PriceGrowth driven by increased adult adoption (70% mix) and outpatient utilization.
Segment GrowthAdult patients now 70% of utilization; pediatric patients 30%.
New ClientsAdded 36 unique ordering accounts this quarter; total now 109.
Capex & DebtRepurchased $30.5M of 2029 notes; reduced outstanding principal by 43%.
RegulatoryCHMP issued negative opinion in EU; closing compassionate use program there.
CommentaryStrategic focus on educating nurses and nephrologists to drive earlier TATMA identification.
New LaunchesLaunched Yard-Temlia late January 2026; NTAP reimbursement effective October 1, 2026.

Growth

Net sales grew 26% quarter-over-quarter; non-GAAP net income rose 161% to $4.7M.

Outlook

Expects higher Q4 operating expenses; targeting first-in-human AML trial for late 2027.

Risks

Management pivoted to vague language when asked for 2027 guidance and specific vial volume splits.

Source

The company's earnings call, NASDAQ: OMER, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Omeros Corporation: key numbers

Share price
$16.68Close, Nov 16
Market cap
$1.24B
Shares outstanding
74.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Omeros Corporation

All →
4:29 PM ET 8-K
Financial Results

Omeros Financial Results

Omeros Corporation reported Q3 2026 financial results, highlighted by a 26% sequential increase in net revenue for YARTEMLEA to $35.9 million. The company reported a GAAP net loss of $57.4 million, primarily driven by a $62.0 million non-cash mark-to-market adjustment on convertible notes, while achieving positive operating cash flow of $13.3 million.

Term
Q3 2026

“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer
5:02 PM ET 8-K
Stock Plan Amendment

Omeros Stock Plan Amendment

Omeros Corporation granted a performance-based stock option award to CEO Gregory A. Demopulos for up to 500,000 shares at an exercise price of $17.88. The award vests across four tranches tied to stock-price hurdles ranging from $25.00 to $40.00 per share and requires continued service over a four-year period. The grant is intended to incentivize long-term shareholder value creation following the company's recent strategic milestones, including FDA approval of YARTEMLEA.

Term
5 years
9:01 PM ET Form 4
Insider Selling

Omeros VP, Finance & CAO David J. Borges Sells $419K of Stock

David J. Borges, VP, Finance & CAO, sold 20,000 shares of Omeros Corp at $20.95 a share, worth $419K in total between Sep 22, 2026 and Sep 23, 2026. Shares held after the trade: 0 (-100.0%).

Value
$419K
Shares
20,000
Average price
$20.95
Role
VP, Finance & CAO
Holding change
-100.0%
Trade date
Sep 22, 2026 to Sep 23, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.